<< Back to News

System Formulary Update
Integrase Strand Transfer Inhibitors (INSTIs)

Situation

The Integrase Strand Transfer Inhibitors class review and formulary standardization was approved at the April 2021 System Pharmacy and Therapeutics Committee meeting.

Background

The following medications were reviewed: dolutegravir, raltegravir, bictegravir, elvitegravir, and combination preparations of the aforementioned agents.

Assessment/Recommendations

Changes Effective: Tuesday July 27, 2021

System P&T voted to include the following products on the UNC Health System Drug Formulary:

• Dolutegravir tablet: 50 mg
• Raltegravir tablet, film-coated: 400 mg
• Bictegravir/emtricitabine/TAF tablet: 50 mg/200 mg/25 mg
• Elvitegravir/cobicistat/emtricitabine/TAF tablet: 150 mg/150 mg/200 mg/10 mg

As a result, the following products will be removed from the inpatient drug formulary:

• Dolutegravir tablet: 25 mg
• Dolutegravir/abacavir/lamivudine (Triumeq) tablet: 50 mg/600 mg/300 mg
• Raltegravir chewable tablet: 100 mg
• Elvitegravir/cobicistat/emtricitabine/TDF (Stribild) tablet: 150 mg/150 mg/200 mg/300 mg